The relationship between subjective well-being and dopamine D2 receptors in patients treated with a dopamine partial agonist and full antagonist antipsychotics

International Journal of Neuropsychopharmacology

Volumn 12, Issue 5, 2009, Pages 715-721

  Mizrahi, Romina ^a,b,d   Mamo, David ^a,b   Rusjan, Pablo ^a   Graff, Ariel ^a   Houle, Sylvain ^a,b   Kapur, Shitij ^c  

^a CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

Antipsychotics; PET; Subjective well being

Indexed keywords

ARIPIPRAZOLE; BENZODIAZEPINE; CLOZAPINE; DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; NEUROLEPTIC AGENT; OLANZAPINE; RACLOPRIDE C 11; RISPERIDONE;

ADULT; AKATHISIA; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG RECEPTOR BINDING; HUMAN; PARTIAL AGONISM; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RATING SCALE; RECEPTOR OCCUPANCY; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SCORING SYSTEM; WELLBEING;

ADULT; AFFECT; ANTIPSYCHOTIC AGENTS; BRAIN; DOPAMINE AGONISTS; DOPAMINE ANTAGONISTS; HUMANS; POSITRON-EMISSION TOMOGRAPHY; PROTEIN BINDING; RECEPTORS, DOPAMINE D2; SCHIZOPHRENIA; YOUNG ADULT;

EID: 69749124350     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S1461145709000327     Document Type: Article

References (31)

1. Arnt J, Skarsfeldt T, Hyttel J (1997). Differentiation of classical and novel antipsychotics using animal models. International Clinical Psychopharmacology 12 (Suppl. 1), S9-17.
2. Bressan RA, Costa DC, Jones HM, Ell PJ, et al. (2002). Typical antipsychotic drugs - D(2) receptor occupancy and depressive symptoms in schizophrenia. Schizophrenia Research 56, 31-36.
3. Burris KD, Molski TF, Xu C, Ryan E, et al. (2002). Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. Journal of Pharmacology and Experimental Therapeutics 302, 381-389.
4. de Haan L, Booij J, Lavalye J, van Amelsvoort T, et al. (2005). Subjective experiences during dopamine depletion. American Journal of Psychiatry 162, 1755.
5. de Haan L, Lavalaye J, Linszen D, Dingemans PM, et al. (2000). Subjective experience and striatal dopamine D(2) receptor occupancy in patients with schizophrenia stabilized by olanzapine or risperidone. American Journal of Psychiatry 157, 1019-1020.
6. de Haan L, Lavalaye J, van Bruggen M, van Nimwegen L, et al. (2004). Subjective experience and dopamine D2 receptor occupancy in patients treated with antipsychotics: clinical implications. Canadian Journal of Psychiatry 49, 290-296.
7. de Haan L, Nimwegen L, Amelsvoort T, Dingemans P, et al. (2008). Improvement of subjective well-being and enduring symptomatic remission: a 5-year follow-up of first episode schizophrenia. Pharmacopsychiatry 41, 125-128.
8. de Haan L, van Bruggen M, Lavalaye J, Booij J, et al. (2003). Subjective experience and D2 receptor occupancy in patients with recent-onset schizophrenia treated with low-dose olanzapine or haloperidol: a randomized, double-blind study. American Journal of Psychiatry 160, 303-309.
9. Deutch AY, Lewis DA, Whitehead RE, Elsworth JD, et al. (1996). Effects of D2 dopamine receptor antagonists on fos protein expression in the striatal complex and entorhinal cortex of the nonhuman primate. Synapse 23, 182-191.
10. Drevets WC, Gautier C, Price JC, Kupfer DJ, et al. (2001). Amphetamine-induced dopamine release in human ventral striatum correlates with euphoria. Biological Psychiatry 49, 81-96.
11. Farde L, Wiesel FA, Hall H, Halldin C, et al. (1987). No D2 receptor increase in PET study of schizophrenia. Archives of General Psychiatry 44, 671-672.
12. Fujita M, Verhoeff NP, Varrone A, Zoghbi SS, et al. (2000). Imaging extrastriatal dopamine D(2) receptor occupancy by endogenous dopamine in healthy humans. European Journal of Pharmacology 387, 179-188.
13. 18F]fallypride PET study. American Journal of Psychiatry 165, 988-995.
14. Kane JM, Carson WH, Saha AR, McQuade RD, et al. (2002). Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. Journal of Clinical Psychiatry 63, 763-771.
15. Karow A, Czekalla J, Dittmann RW, Schacht A, et al. (2007). Association of subjective well-being, symptoms, and side effects with compliance after 12 months of treatment in schizophrenia. Journal of Clinical Psychiatry 68, 75-80.
16. Kay SR, Fiszbein A, Opler LA (1987). The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophrenia Bulletin 13, 261-276.
17. Lammertsma AA, Hume SP (1996). Simplified reference tissue model for PET receptor studies. Neuroimage 4, 153-158.
18. Mamo D, Graff A, Mizrahi R, Shammi CM, et al. (2007). Differential effects of aripiprazole on D(2), 5-HT(2), and 5-HT(1A) receptor occupancy in patients with schizophrenia: a triple tracer PET study. American Journal of Psychiatry 164, 1411-1417.
19. Marder SR (2005). Subjective experiences on antipsychotic medications: synthesis and conclusions. Acta Psychiatrica Scandinavica (Suppl.), 427, 43-46.
20. Mawlawi O, Martinez D, Slifstein M, Broft A, et al. (2001). Imaging human mesolimbic dopamine transmission with positron emission tomography. I. Accuracy and precision of D(2) receptor parameter measurements in ventral striatum. Journal of Cerebral Blood Flow and Metabolism 21, 1034-1057.
21. Mizrahi R, Rusjan P, Agid O, Graff A, et al. (2007). Adverse subjective experience with antipsychotics and its relationship to striatal and extrastriatal D2 receptors: a PET study in schizophrenia. American Journal of Psychiatry 164, 630-637.
22. Naber D, Moritz S, Lambert M, Pajonk FG, et al. (2001). Improvement of schizophrenic patients' subjective well-being under atypical antipsychotic drugs. Schizophrenia Research 50, 79-88.
23. Natesan S, Reckless GE, Nobrega JN, Fletcher PJ, et al. (2006). Dissociation between in vivo occupancy and functional antagonism of dopamine D2 receptors: comparing aripiprazole to other antipsychotics in animal models. Neuropsychopharmacology 31, 1854-1863.
24. Rusjan P, Mamo D, Ginovart N, Hussey D, et al. (2006). An automated method for the extraction of regional data from pet images. Psychiatry Research 147, 79-89.
25. Sokoloff P, Giros B, Martres MP, Bouthenet ML, et al. (1990). Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature 347, 146-151.
26. Verhoeff NP, Christensen BK, Hussey D, Lee M, et al. (2003). Effects of catecholamine depletion on D2 receptor binding, mood, and attentiveness in humans: a replication study. Pharmacology Biochemistry and Behavior 74, 425-432.
27. Verhoeff NP, Kapur S, Hussey D, Lee M, et al. (2001). A simple method to measure baseline occupancy of neostriatal dopamine D2 receptors by dopamine in vivo in healthy subjects. Neuropsychopharmacology 25, 213-223.
28. Voruganti L, Awad AG (2004). Neuroleptic dysphoria: towards a new synthesis. Psychopharmacology (Berlin) 171, 121-132.
29. Voruganti L, Slomka P, Zabel P, Costa G, et al. (2001). Subjective effects of AMPT-induced dopamine depletion in schizophrenia: correlation between dysphoric responses and striatal D(2) binding ratios on SPECT imaging. Neuropsychopharmacology 25, 642-650.
30. Wise RA (2002). Brain reward circuitry: insights from unsensed incentives. Neuron 36, 229-240.
31. 11C]raclopride. Neuropsychopharmacology 27, 248-259.